Link to this page
Physician Data Query
Last uploaded:
August 28, 2024
Jump to:
| Preferred Name | febuxostat | |
| Synonyms |
2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid Uloric TMX 67 |
|
| Definitions |
An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies. |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000743107 |
|
| altLabel |
2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid Uloric TMX 67
|
|
| CAS Registry |
144060-53-7
|
|
| cui |
C2713017 C2683462 C0249529
|
|
| DATE FIRST PUBLISHED |
2012-11-20
|
|
| Date last modified |
2012-11-20
|
|
| definition |
An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.
|
|
| LT |
TRD
|
|
| notation |
CDR0000743107
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
febuxostat
|
|
| tui |
T109 T121
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping